Physician profile
Muhammad Anwar
NPI 1730164922
$3,853.37
in general payments reported to CMS, 2019-2025
20 companies · $897 in 2025
The $897 reported for 2025 was more than what 93% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $26.62 · 2021: $184 · 2022: $563 · 2023: $844 · 2024: $1,135 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,876.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $959.41 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $833.06 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $426.82 | 2022-2025 | Stelara, Tremfya, Simponi |
| Qol Medical, LLC | $412.56 | 2021-2024 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.17 | 2021-2023 | Trulance |
| Intercept Pharmaceuticals, INC. | $179.03 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $141.15 | 2024-2025 | Ibsrela |
| Celgene Corporation | $128.58 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $117.86 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $87.10 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $76.21 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $53.30 | 2019-2024 | Rebyota |
| Redhill Biopharma INC. | $25.41 | 2022 | |
| Mirum Pharmaceuticals, INC. | $22.08 | 2025 | Livmarli, Cholbam, Chenodal |
| Genzyme Corporation | $21.76 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $19.82 | 2024 | Idacio |
| Exact Sciences Corporation | $19.41 | 2025 | Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $15.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.88 | 2024 | Cyltezo |
| Vivus LLC | $14.47 | 2025 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.